Askbio Inc.

Askbio Inc. company information, Employees & Contact Information

Explore related pages

Related company profiles:

AskBio Inc., a wholly owned and independently operated subsidiary of Bayer AG, is a fully integrated gene therapy company dedicated to developing life-saving medicines and changing lives. The company maintains a portfolio of clinical programs across a range of neuromuscular, central nervous system, cardiovascular and metabolic disease indications with a clinical-stage pipeline that includes therapeutics for congestive heart failure, limb-girdle muscular dystrophy, multiple system atrophy, Parkinson’s disease, and Pompe disease. AskBio’s gene therapy platform includes Pro10™, an industry-leading proprietary cell line manufacturing process, and an extensive capsid and promoter library. With global headquarters in Research Triangle Park, North Carolina, and European headquarters in Edinburgh, Scotland, the company has generated hundreds of proprietary capsids and promoters, several of which have entered pre-clinical and clinical testing. Learn more at askbio.com. Vision - Pioneering science to create transformative molecular medicines. Mission - Lead innovative science and drive clinical outcomes to transform people's lives. Values: • Be a Pioneer. We are not afraid of the impossible and to innovate to make gene therapies accessible to those in need. • Cultivate Collaboration. Strive to be the best teammate, actively listen, openly communicate, and embrace diverse points of view. • Embrace Responsibility. We are humbled by the enormity of our mission. We hold a relentless commitment to advance science and clinical outcomes for our patients, families, and caregivers. • Raise the Bar. Continuously drive improvements and efficiencies. Seek and provide constructive feedback. Have a bias for learning and action. • Act with Uncompromising Integrity. Be honest, transparent, and committed to doing what’s right in every situation. Make clear commitments and follow through.

Company Details

Employees
512
Address
20 Tw Alexander Dr, Suite 110,united States
Phone
+1 (919) 561-6210
Industry
Biotechnology Research
NAICS
Research and Development in Biotechnology (except Nanobiotechnology)
Website
askbio.com
HQ
Research Triangle Park, North Carolina
Looking for a particular Askbio Inc. employee's phone or email?

Askbio Inc. Questions

News

AskBio Presents Interim Safety Results from Phase 1/Phase 2 LION-CS101 Clinical Trial of AB-1003 in Participants with Limb-Girdle Muscular Dystrophy 2I/R9 - Bayer

AskBio Presents Interim Safety Results from Phase 1/Phase 2 LION-CS101 Clinical Trial of AB-1003 in Participants with Limb-Girdle Muscular Dystrophy 2I/R9 Bayer

AskBio Announces Publication in Nature Medicine of 12-month - GlobeNewswire

AskBio Announces Publication in Nature Medicine of 12-month GlobeNewswire

AskBio Announces Completion of Enrollment in Phase 1 Clinical Trial of AB-1005 Gene Therapy for Multiple System Atrophy-Parkinsonian Type (MSA-P) - Yahoo Finance

AskBio Announces Completion of Enrollment in Phase 1 Clinical Trial of AB-1005 Gene Therapy for Multiple System Atrophy-Parkinsonian Type (MSA-P) Yahoo Finance

AskBio Announces Publication of Complete Results of Phase 1b Trial of AB-1005 Gene Therapy in Participants with Parkinson’s Disease in Movement Disorders - Bayer

AskBio Announces Publication of Complete Results of Phase 1b Trial of AB-1005 Gene Therapy in Participants with Parkinson’s Disease in Movement Disorders Bayer

AskBio Announces 6 Presentations at the European Society of Gene and Cell Therapy 32nd Annual Meeting - Yahoo Finance

AskBio Announces 6 Presentations at the European Society of Gene and Cell Therapy 32nd Annual Meeting Yahoo Finance

Patients Treated With AskBio’s Limb-Girdle Muscular Dystrophy Gene Therapy AB-1003 Free of Serious Adverse Events at Up to 52 Weeks - CGTLive®

Patients Treated With AskBio’s Limb-Girdle Muscular Dystrophy Gene Therapy AB-1003 Free of Serious Adverse Events at Up to 52 Weeks CGTLive®

AskBio Receives FDA Regenerative Medicine Advanced Therapy designation for Parkinson’s disease investigational gene therapy - Bayer

AskBio Receives FDA Regenerative Medicine Advanced Therapy designation for Parkinson’s disease investigational gene therapy Bayer

First European Participants Randomized in AskBio Phase 2 Gene Therapy Trial of AB-1005 for Parkinson’s Disease - GlobeNewswire

First European Participants Randomized in AskBio Phase 2 Gene Therapy Trial of AB-1005 for Parkinson’s Disease GlobeNewswire

First participants randomized in AskBio Phase II gene therapy trial for Parkinson’s disease - Yahoo Finance

First participants randomized in AskBio Phase II gene therapy trial for Parkinson’s disease Yahoo Finance

AskBio to collaborate with Belief BioMed to explore the potential of new gene therapies - Bayer

AskBio to collaborate with Belief BioMed to explore the potential of new gene therapies Bayer

AskBio Advances Gene Therapy Clinical Trial for Limb-Girdle - GlobeNewswire

AskBio Advances Gene Therapy Clinical Trial for Limb-Girdle GlobeNewswire

AskBio Presents Complete Results of Phase 1 Trial of - GlobeNewswire

AskBio Presents Complete Results of Phase 1 Trial of GlobeNewswire

AskBio Elects Dr. Laura Sepp-Lorenzino Independent Member of Board of Directors - Bayer

AskBio Elects Dr. Laura Sepp-Lorenzino Independent Member of Board of Directors Bayer

AskBio Announces 15 Presentations at American Society of Gene and Cell Therapy 28th Annual Meeting - GlobeNewswire

AskBio Announces 15 Presentations at American Society of Gene and Cell Therapy 28th Annual Meeting GlobeNewswire

First Participant Randomized in Europe in AskBio Phase 2 Gene Therapy Trial for Congestive Heart Failure - Bayer

First Participant Randomized in Europe in AskBio Phase 2 Gene Therapy Trial for Congestive Heart Failure Bayer

AskBio Initiates Recruitment to its Phase 2 Parkinson’s Disease Trial - Bayer

AskBio Initiates Recruitment to its Phase 2 Parkinson’s Disease Trial Bayer

Bayer’s AskBio initiates Phase II GenePHIT trial in Congestive Heart Failure (CHF) - Bayer

Bayer’s AskBio initiates Phase II GenePHIT trial in Congestive Heart Failure (CHF) Bayer

AskBio Presents Preliminary Data from Phase 1 Trial of Gene Therapy for Congestive Heart Failure (CHF) at the 2023 American Heart Association Scientific Sessions - Bayer

AskBio Presents Preliminary Data from Phase 1 Trial of Gene Therapy for Congestive Heart Failure (CHF) at the 2023 American Heart Association Scientific Sessions Bayer

AskBio Announces 11 Presentations at the European Society of Gene and Cell Therapy 31st Annual Meeting 2024 - GlobeNewswire

AskBio Announces 11 Presentations at the European Society of Gene and Cell Therapy 31st Annual Meeting 2024 GlobeNewswire

AskBio Announces Gustavo Pesquin as New CEO - Bayer

AskBio Announces Gustavo Pesquin as New CEO Bayer

First patient randomized in AskBio Phase II gene therapy trial for congestive heart failure - Bayer

First patient randomized in AskBio Phase II gene therapy trial for congestive heart failure Bayer

AskBio Announces Strategic Collaboration with ReCode Therapeutics to Explore Single Vector Gene Editing Platform - Bayer

AskBio Announces Strategic Collaboration with ReCode Therapeutics to Explore Single Vector Gene Editing Platform Bayer

AskBio Phase Ib trial of AB-1005 gene therapy in patients with Parkinson’s disease meets primary endpoint - Bayer

AskBio Phase Ib trial of AB-1005 gene therapy in patients with Parkinson’s disease meets primary endpoint Bayer

First Patient Randomized in AskBio Phase II Gene Therapy Trial for Congestive Heart Failure Treatment - Diagnostic and Interventional Cardiology

First Patient Randomized in AskBio Phase II Gene Therapy Trial for Congestive Heart Failure Treatment Diagnostic and Interventional Cardiology

AskBio Announces First Patient Randomized in Phase 1 Trial of AB-1005 (AAV2-GDNF) Gene Therapy for Multiple System Atrophy-Parkinsonian Type (MSA-P) - Bayer

AskBio Announces First Patient Randomized in Phase 1 Trial of AB-1005 (AAV2-GDNF) Gene Therapy for Multiple System Atrophy-Parkinsonian Type (MSA-P) Bayer

AskBio Announces Initiation of Phase 2 GenePHIT Trial in Congestive Heart Failure (CHF) - Diagnostic and Interventional Cardiology

AskBio Announces Initiation of Phase 2 GenePHIT Trial in Congestive Heart Failure (CHF) Diagnostic and Interventional Cardiology

LGMD is a Rare Form of Muscular Dystrophy with No Approved Therapies - Bayer

LGMD is a Rare Form of Muscular Dystrophy with No Approved Therapies Bayer

AskBio Announces Nine Presentations at American Society of Gene and Cell Therapy 27th Annual Meeting 2024 - GlobeNewswire

AskBio Announces Nine Presentations at American Society of Gene and Cell Therapy 27th Annual Meeting 2024 GlobeNewswire

AskBio Acquires Synpromics Ltd. and Expands its Gene Therapy Technology Portfolio - PR Newswire

AskBio Acquires Synpromics Ltd. and Expands its Gene Therapy Technology Portfolio PR Newswire

AskBio Acquires Assets from RoverMed BioSciences, Adds Nanotechnology Precision to Delivery of AAV Gene Therapeutics - PR Newswire

AskBio Acquires Assets from RoverMed BioSciences, Adds Nanotechnology Precision to Delivery of AAV Gene Therapeutics PR Newswire

AskBio Applauds Pfizer's Continuing Investments in Gene Therapy - PR Newswire

AskBio Applauds Pfizer's Continuing Investments in Gene Therapy PR Newswire

Synpromics deal significantly exceeds returns for investors including Calculus and Scottish Investment Bank - scottish-enterprise-mediacentre.com

Synpromics deal significantly exceeds returns for investors including Calculus and Scottish Investment Bank scottish-enterprise-mediacentre.com

Top Askbio Inc. Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant